Effect of Deep Neuromuscular Block on Surgical Conditions in Morbidly Obese Patients
NCT ID: NCT02553629
Last Updated: 2017-02-03
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
109 participants
INTERVENTIONAL
2015-09-30
2016-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Surgical Conditions During Laparoscopic Bariatric Surgery
NCT02703909
Laparoscopic Bariatric Surgery: Impact of Deep Neuromuscular Block on Surgical Conditions
NCT02118844
Pharmacodynamic Trial on Rocuronium in Obese Patients
NCT00540085
Neuromuscular Blockade: Outcome and Recovery for Laparoscopic Bariatric Surgery
NCT02300168
Determinants on Rocuronium Dose for Deep Block in Bariatric Surgery
NCT04709406
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
moderate neuromuscular block
rocuronium 0.1-0.6 mg/kg aimed at a train of four of 1 - 2 twitches
Rocuronium
deep neuromuscular block
rocuronium 0.1-0.6 mg/kg aimed at a post tetanic count of 1 - 2 twitches
Rocuronium
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Rocuronium
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI \> 34 kg/m2
* Elective bariatric surgery.
Exclusion Criteria
* Allergies to muscle relaxants, anesthetics or narcotics
* A(family) history of malignant hyperthermia
* Women who are or may be pregnant or are currently breast feeding
* Renal insufficiency, as defined by serum creatinine x 2 of normal, or urine output \< 0.5 ml/kg/h for at least 6 h.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck Sharp & Dohme LLC
INDUSTRY
Medical Center Haaglanden
OTHER
Leiden University Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Albert Dahan
MD, PhD, professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Albert Dahan, MD, PhD, professor
Role: PRINCIPAL_INVESTIGATOR
LUMC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Leiden University Medical Center
Leiden, South Holland, Netherlands
Medisch Centrum Haaglanden / Nederlandse Obesitas Kliniek
The Hague, South Holland, Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NL52829.058.15
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.